KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) Debt to Equity (2023 - 2025)

Biocryst Pharmaceuticals' Debt to Equity history spans 8 years, with the latest figure at -$0.32 for Q4 2025.

  • For Q4 2025, Debt to Equity rose 55.8% year-over-year to -$0.32; the TTM value through Dec 2025 reached -$0.32, up 55.8%, while the annual FY2025 figure was -$0.32, 55.8% up from the prior year.
  • Debt to Equity reached -$0.32 in Q4 2025 per BCRX's latest filing, up from -$0.6 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of -$0.32 in Q4 2025 to a low of -$0.77 in Q1 2025.
  • Average Debt to Equity over 3 years is -$0.68, with a median of -$0.72 recorded in 2023.
  • The largest YoY upside for Debt to Equity was 55.8% in 2025 against a maximum downside of 10.16% in 2025.
  • A 3-year view of Debt to Equity shows it stood at -$0.72 in 2023, then dropped by 1.79% to -$0.73 in 2024, then surged by 55.8% to -$0.32 in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Debt to Equity are -$0.32 (Q4 2025), -$0.6 (Q3 2025), and -$0.66 (Q2 2025).